retatrutide phase 3 results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Eli Lilly infiltrates anti-obesity market

not a guarantee for any compounded product or any individual patient SURMOUNT-1 trial (NEJM): 20.9% average body weight loss with tirzepatide - same qualification

"Build healthy eating habits, stay active, and get support for the emotional side of weight loss." Resources We Trust Cleveland Clinic: GLP-1 Agonists Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss JAMA Internal Medicine: I Am Taking a GLP-1 Weight-Loss Medication What Should I Know

In the UK, Graham Phillips describes himself as the pharmacist who gave up drugs and runs two pharmacies, in Letchworth and Broadstairs, that offer a prolongevity programme that promotes weight loss through natural means, such as cutting out ultra-processed foods and monitoring blood glucose levels

In a study of 3,731 patients assigned to take either liraglutide or placebo, 63.2% of patients taking liraglutide lost at least 5% of their body weight and 33.1% of patients lost at least 10% of their body weight

Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T

A landmark study published in Diabetes (Tolhurst et al., 2012) demonstrated that SCFAs stimulate GLP-1 secretion via the FFAR2 receptor, and that mice lacking this receptor showed significantly reduced SCFA-triggered GLP-1 release